Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

What Is the Auspitz Sign? Auspitz sign is a distinctive mark seen when a skin plaque has been removed. Plaques (also called scales) are common in plaque psoriasis, but people with Darier′s disease and ...

You notice a scaly, itchy rash on your skin and immediately start wondering what’s causing it. Two common culprits that can look surprisingly similar are psoriasis and ringworm, but getting the right ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Vtama is a nonsteroidal cream for plaque psoriasis. Plaque psoriasis is a condition where the immune system causes the skin to make too many new cells too quickly. These extra skin cells pile up on ...

Even as the prevalence of psoriasis increases around the world, with the highest proportions found in white populations, there is apparently a greater burden of disease among populations with skin of ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Kim Kardashian has it ... along with Olympians, singers and TV's "Beaver." Kim Kardashian arrives for The Hollywood Reporter's 22nd Annual Women In Entertainment Breakfast at the Beverly Hills Hotel ...

Psoriasis is an autoimmune disease that affects over 7.5 million adults in the United States. It’s a chronic condition that currently has no cure. Plaque psoriasis is the most common type, accounting ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...